Previous 10 | Next 10 |
Horizon Technology Finance Provides Third Quarter 2021 Portfolio Update - Horizon Platform Originates Record $141 Million of New Loans - - Record $99 Million of Originations for HRZN - - Horizon Platform Committed Backlog of $123 Million; $101 Million in HRZN Commitments...
Stealth BioTherapeutics Completes a $25 Million Debt Financing with Horizon Technology Finance PR Newswire BOSTON , Oct. 4, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, developm...
Sonoma Pharmaceuticals (NASDAQ:SNOA) +70% on product launch in U.S. and Europe Planet Green (NYSE:PLAG) +30%. ZIVO Bioscience (NASDAQ:ZIVO) +20%. Frequency Electronics (NASDAQ:FEIM) +17% wins contract from the Office of Naval Research for atomic clock development AGM Group...
Stealth BioTherapeutics Presents Positive SBT-272 Preclinical Data at International Parkinson and Movement Disorder Society Virtual Congress 2021 Clinical-stage product candidate SBT-272 shows promise in neurodegenerative disease model PR Newswire BOSTON , ...
Stealth BioTherapeutics to Showcase Leadership in Retinal Mitochondrial Health with Clinical Updates at Ophthalmic Conferences PR Newswire BOSTON , Sept. 14, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology com...
Stealth BioTherapeutics to Present at Upcoming September Virtual Investor Conferences PR Newswire BOSTON , Sept. 7, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development...
Stealth BioTherapeutics Submits Elamipretide New Drug Application to FDA for Treatment of Barth Syndrome PR Newswire BOSTON , Aug. 24, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discover...
Stealth BioTherapeutics Strengthens IP Portfolio with Issuance of U.S. Patents Covering Elamipretide for Barth Syndrome PR Newswire BOSTON , Aug. 23, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused ...
Stealth BioTherapeutics to Present at H.C. Wainwright Ophthalmology Virtual Healthcare Conference PR Newswire BOSTON , Aug. 11, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery,...
Stealth BioTherapeutics Corp (MITO) Q2 2021 Earnings Conference Call August 05, 2021, 08:30 ET Company Participants Henry Hess - Chief Legal Counsel Irene McCarthy - President, CEO, Secretary & Director James Carr - Chief Clinical Development Officer Brian Blakey - Chief Business Officer ...
News, Short Squeeze, Breakout and More Instantly...
Stealth BioTherapeutics Corp. Company Name:
MITO Stock Symbol:
NYSE Market:
Stealth BioTherapeutics Corp. Website:
Stealth BioTherapeutics Corp Announces Completion of Merger PR Newswire BOSTON , Nov. 16, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO) (the "Company" or "Stealth BioTherapeutics"), a clinical-stage biotechnology company focused on the ...
Stealth BioTherapeutics Announces SBT-272 Data Updates and Orphan Drug Designation for the Treatment of Amyotrophic Lateral Sclerosis (ALS) PR Newswire SBT-272 Phase 1 safety and tolerability data support further clinical development SBT-272 was neuroprotective...
Stealth BioTherapeutics Corp to Hold Extraordinary General Meeting of Shareholders PR Newswire BOSTON , Oct. 7, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO) ("Stealth" or the "Company"), a clinical-stage biotechnology company focused o...